

Serotypes and susceptibility of *Streptococcus pneumoniae* strains isolated from children in Mexico

Alberto Villaseñor-Sierra, MD, ⁽¹⁾ Maricarmen Lomas-Bautista, MD, ⁽¹⁾
Sergio Aguilar-Benavides, MD, ⁽²⁾ Gerardo Martínez-Aguilar, MD. ⁽³⁾

Villaseñor-Sierra A, Lomas-Bautista M, Aguilar-Benavides S, Martínez-Aguilar G. Serotypes and susceptibility of *Streptococcus pneumoniae* strains isolated from children in Mexico. *Salud Publica Mex* 2008;50:330-333.

Abstract

Objective. To identify serotypes and susceptibility of *S. pneumoniae* strains from 48 children with invasive infections and 50 carriers. **Material and Methods.** Typing was performed by the Quellung reaction and susceptibility by Kirby-Bauer and Etest according to CLSI standards. **Results.** Of 31 meningial strains, serotypes 19F, 3, 6B, 14 and 23F were predominant. Resistance to penicillin and STX was 16 and 58%, respectively; of 17 invasive non-meningial strains, serotypes 19F and 3 were predominant and resistance to penicillin and SXT was 0 and 82%, respectively; of carrier strains, serotypes 6A, 6B, 19F and 23F were predominant. **Conclusions.** A 10-valent conjugate vaccine could offer a better coverage for meningial strains.

Key words: *Streptococcus pneumoniae*; serotyping; vaccines, conjugate; susceptibility; anti-infective agents; child, preschool; child; Mexico

Villaseñor-Sierra A, Lomas-Bautista M, Aguilar-Benavides S, Martínez-Aguilar G. Serotipos y susceptibilidad de cepas de *Streptococcus pneumoniae* aisladas de niños en México. *Salud Publica Mex* 2008;50:330-333.

Resumen

Objetivo. Identificar serotipos y susceptibilidad en cepas aisladas de 48 niños con infecciones invasivas y de 50 portadores. **Material y métodos.** Serotipificación mediante reacción de Quellung y susceptibilidad mediante Kirby-Bauer y E-test. **Resultados.** De 31 cepas meningíneas, predominaron serotipos 19F, 3, 6B, 14 y 23F y la resistencia a penicilina (P) y trimetoprim-sulfametoxazol (SXT) fue de 16 y 58%. En 17 cepas invasivas no meningíneas, predominaron serotipos 19F y 3 y la resistencia a P y SXT fue de 0 y 82%, en cada caso. En portadores predominaron serotipos 6A, 6B, 19F y 23F. **Conclusiones.** La resistencia es similar a otros informes. La vacuna conjugada 10-valente podría ofrecer mejor cobertura para serotipos asociados a meningitis.

Palabras clave: *Streptococcus pneumoniae*; serotipificación; vacunas conjugadas; susceptibilidad; agentes antiinfecciosos; preescolar; niño; México

- (1) Centro de Investigación Biomédica de Occidente. Instituto Mexicano del Seguro Social. Guadalajara, Mexico.
(2) UMAE Hospital de Pediatría, Instituto Mexicano del Seguro Social. Guadalajara, Mexico
(3) Centro de Investigación Biomédica, Instituto Mexicano del Seguro Social. Durango, Mexico.

Received on: August 9, 2007 • Accepted on: April 4, 2008

Address reprint requests to: Dr. Alberto Villaseñor. Centro de Investigación Biomédica de Occidente. Instituto Mexicano del Seguro Social. Sierra Mojada 800 Col. Independencia. 44340 Guadalajara, Jalisco.
E-mail: avillase@prodigy.net.mx

Streptococcus pneumoniae (Pn) is the leading cause of invasive infections in children, including meningitis pneumonia, bacteremia and acute otitis media. It is also carried in the nasopharynx of asymptomatic children and adults. Although 90 serotypes have been described, only a few of these (4, 14, 18C, 23F, 6B, 19A, 19F, 6A, 9V and 9B) have been associated with antimicrobial-resistance and invasive infections in children younger than two years old.^{1,2} The pneumococcal heptavalent conjugated vaccine (Pn-7vccv) was developed based on the seven most prevalent serotypes associated with invasive infections in children from the United States of America (USA).^{1,3} This vaccine had an efficacy of 93.9% in one intent-to-treat analysis of a double blind clinical trial study conducted in the USA.³ However, several serotypes associated with invasive infections in some Navajo Indian communities in the USA⁴ as well as in Saudi Arabia,⁵ Egypt,⁶ and various countries of Latin America^{2,7} are not included in the Pn-7vccv.

By identifying *S. pneumoniae* serotypes isolated from patients with invasive infections and carriers, we can explore the adequacy of the current seven-valent pneumococcal conjugated vaccine as well as that of other candidate vaccines containing a greater number of serotypes, such as the eleven-valent conjugate vaccine (recently reduced into a ten-valent one (Pn-10vccv) by elimination of serotype 3).^{4,6,8} This will help to determine if available conjugate vaccines are adequate or if specific vaccines need to be formulated for use in Latin American countries.

An additional issue in the treatment of patients with invasive pneumococcal infections is the increasing prevalence of penicillin (minimum inhibitory concentration $\geq 2 \mu\text{g/mL}$) and multi-drug resistant strains.^{2,7,9} In Mexico, a previous report demonstrated that resistance to penicillin, erythromycin and trimethoprim-sulfamethoxazole was elevated (20.8, 24.5 and 58.9%, respectively).⁷

The aims of the present study were to identify capsular serotypes and antimicrobial susceptibility profiles of *S. pneumoniae* strains isolated from children with invasive infections and from healthy nasopharyngeal carriers (NPC). We also determined the percent of potential coverage of the serotypes included in the Pn-7vccv and Pn-10vccv.

Material and Methods

This cross-sectional study was performed between March 2000 and May 2005. Protocol was approved by the IMSS Local Research and Ethics Committee (No. F. 2005-1302-022). Informed consent was obtained from the parents of the children attending day-care centers before

taking nasopharyngeal cultures. *S. pneumoniae* strains were isolated both from cultures taken in children with invasive infections seen in a tertiary reference children's hospital and from nasopharyngeal cultures of healthy non-vaccinated children attending day-care centers in the metropolitan area of Guadalajara, Mexico, and used for comparative purposes.

All the strains were identified by conventional microbiological procedures. Antimicrobial susceptibility to chloramphenicol (C; 30 μg), vancomycin (Va; 30 μg), erythromycin (E; 15 μg), and trimethoprim-sulfamethoxazole (STX; 1,25:23.75) (BBL Becton Dickinson, Sparks USA) was determined by disc diffusion (Kirby-Bauer) in Mueller-Hinton agar with 5% sheep blood, and interpreted according to the criteria of the Clinical Laboratory Standards Institute (CLSI), USA (document M100 S16, 2006).¹⁰ Susceptibility to penicillin (P) was determined by Etest strips (AB BIODISK Solna, Sweden) only for strains isolated from invasive infections, and they were interpreted according to the CLSI criteria. For strains isolated from the cerebrospinal fluid (CSF) of children with meningitis, strains were considered resistant to penicillin if the MIC $\geq 2 \mu\text{g/mL}$. *S. pneumoniae* strain ATCC 49619 was used for quality control.

Serogrouping-serotyping was performed in the Infectious Disease Laboratory of the Texas Children's Hospital of Houston, Texas with the Quellung reaction, using sera produced by the Statens Seruminstitut, Copenhagen, Denmark.

Results

Forty-eight *S. pneumoniae* strains were recovered from the children with invasive infections. Another 50 strains were isolated from the nasopharynx of the healthy non-vaccinated children.

Invasive strains were isolated from the children with an age range of 1-12 years (mean = $4.7 \pm \text{S.D. } 4.3$); 55% were males. Non-invasive strains were isolated from NPC of similar age range (2 to 13 years, mean = $5.5 \pm \text{SD } 2.9$) and gender distribution.

Of the 48 invasive strains (INV), 31 (65%) were recovered from the CSF of patients with meningitis, and seventeen (35%) from other normally sterile sites; 11 from middle ear effusion in acute otitis media patients, one from a patient with mastoiditis; two from blood cultures of pneumonia patients; two from patients with peritonitis and one from acute endophthalmitis.

The serotypes isolated from 31 children with meningitis were: 1, 3, 4, 6A, 6B, 7F, 9V, 11, 14, 19A, 19F, 23F, 31, and non-typeable. From those, serotype 19F was the most frequently isolated (16%) followed by 3 (13%), 6B (13%), and 14 (13%). Twelve serotypes accounted for

90% of the isolates. The proportion of serotypes included in both the Pn-7vcv and the Pn-10vcv was 58 and 65%, respectively (Table I).

The *S. pneumoniae* serotypes isolated from each of the non-meningitis invasive infections were: acute otitis media (19F, 3, 11, 19A, 29-35-42, and non-typeable); pneumonia (19F, 35); peritonitis (19F); endophthalmitis (6A), and mastoiditis (3). Serotype 19F was the most frequently isolated (29%), followed by serotype 3 (18%). Nine serotypes accounted for 88% of the isolates. The proportion of serotypes included in both the Pn-7vcv and the Pn-10vcv was 29% (table I).

Twenty-one serotypes were isolated from 50 carriers: 3, 6A, 6B, 7, 10, 11, 14, 15, 17, 18A, 18C, 19A, 19F, 23A, 23F, 28, 29-34-25-42, 29-35-42, 35B, 6-29-35-42, and non-typeable. Of these, the most prevalent serotypes were: 6B (18%); 19F (16%); 23F (8%) and 6A (8%). Nineteen serotypes accounted for 90% of the isolates. The proportion of serotypes included in both the Pn-7vcv and the Pn-10vcv was 48% (table I).

None of the 98 strains was resistant to vancomycin or ceftriaxone. From CSF strains, 16% were resistant to penicillin (MIC ≥ 2 μ g/mL). Resistance to erythromycin was higher and resistance to SXT was lower than in those from other invasive infections. No resistance to penicillin was detected among the strains isolated from other invasive infections. In NPC, resistance to erythromycin was higher (30%) and resistance to SXT was lower (56%) than in the strains isolated from CSF (23 and 58%, respectively) (table I). Of those strains resistant (including intermediate) to penicillin, chloranphenicol, erythromycin or trimethoprim-sulfamethoxazole, almost half (50, 50, 55, and 52%, respectively) belonged

to serotypes included either in the 7th or 10th valent conjugate vaccines.

Discussion

It has been reported that Pn-7vcv offers good protection for the USA Caucasian population. However, several authors have demonstrated an inferior coverage of this vaccine for *S. pneumoniae* serotypes associated with invasive diseases in Saudi Arabia, Egypt,^{5,6} indigenous communities (Navajos) of the southwestern USA,⁴ and several Latin American countries.^{2,7} In these cases, Pn-10vcv could provide better coverage for those serotypes associated with invasive infections in children when available.^{2,4,5,7,8}

In this study, the serotypes identified were similar to those described by other authors in Latin American countries,^{2,7} Asia,¹¹ and Russia,¹² showing a worldwide distribution of certain serotypes. We found that a slightly higher proportion of *S. pneumoniae* serotypes isolated from children with meningitis (7%) were included in the Pn-10vcv than in the Pn-7vcv. However, no differences in serotypes coverage by the 7-valent or 10-valent conjugate vaccines was found in strains isolated from non-CSF invasive strains and from non-vaccinated NPC. The typing of nasopharyngeal isolates is useful as baseline information for future studies in vaccinated populations, in which we can expect a shift towards and replacement by non-vaccine serotypes¹³.

Although the number of strains reported is limited, they were collected during a four-year period in a tertiary referral hospital that provides medical care to roughly 40% of the children living in a state of 6.9 million

Table I

SEROTYPES, ANTIMICROBIAL SUSCEPTIBILITY AND PROPORTION OF THOSE INCLUDED IN 7- OR 10-VALENT CONJUGATE VACCINES OF 98 *S. PNEUMONIAE* STRAINS ISOLATED FROM CHILDREN WITH MENINGITIS (N= 31), OTHER INVASIVE INFECTIONS (N= 17) AND FROM NASOPHARYNGEAL CARRIERS (N= 50) FROM GUADALAJARA, MEXICO BETWEEN MARCH 2000 AND MAY 2005

Source of strains	Serotypes	Vaccine Serotypes		Susceptibility											
		Pn-7vcv (%)	Pn-10vcv (%)	P (MIC)			E			STX			C		
				S (%)	I (%)	R (%)	S (%)	I (%)	R (%)	S (%)	I (%)	R (%)	S (%)	I (%)	R (%)
Meningitis (CSF)	1, 3, 4, 7F, 11, 14, 19A, 19F, 23F, 31, Non-typeable	58	65	36	48	16	74	3	23	26	16	58	97	0	3
Other Invasive	3, 6A, 11, 19A, 19F, 29, 35, 42, Non-typeable	29	29	47	3	0	76	6	18	18	0	82	88	0	12
NPC	3, 6A, 6B, 7C, 10, 11, 13, 14, 15, 17, 18A, 18C, 19A, 19F, 23A, 23F, 29, 34, 35B, 42, non-typeable	48	48	ND	ND	ND	62	8	30	36	8	56	94	0	6

P (MIC): Minimal inhibitory concentration of Penicillin

E: Erythromycin

STX: Trimethoprim-sulfamethoxazole

C: Chloranphenicol

S: Susceptible

I: Intermediate

R: Resistant

ND: Not done

7vcv: seven serotypes conjugate vaccines

10vcv: ten serotypes conjugate vaccines

CSF: cerebrospinal fluid

NPC: nasopharyngeal carriers

inhabitants. Our findings show important similarities to the serotypes associated with invasive disease in other Latin American and Asian countries.

The number of non-susceptible strains to penicillin (considering intermediate and resistant strains together) was high (64%) in children with meningitis. We also found a higher percentage of strains with intermediate resistance than that in other reports from Latin American countries.⁷ However, all of these strains remained susceptible to vancomycin. The moderate level of resistance to erythromycin and the high level to trimethoprim-sulfamethoxazole found in the present study agree with the reports from other parts of the world suggesting a worldwide spread of certain clones.^{6,7,14}

In conclusion, the number of serotypes isolated from patients with invasive infections and included in the Pn-10vcv was slightly superior than those included in the Pn-7vcv. The number of strains with diminished susceptibility to penicillin, moderate resistance to erythromycin, and high resistance to trimethoprim-sulfamethoxazole could be associated with the abuse of antimicrobial prescriptions or with the intercontinental spread of multi-resistant strains. At least half of the serotypes with resistance to the antimicrobials tested belonged to the ones included in the 7 or 10 valent conjugate vaccines.

Acknowledgments

This study was supported in part by Grant D43 TW01036 from the Fogarty International Center of the National Institutes of Health. This work was presented in part in the 106th General Meeting of the American Society for Microbiology, Orlando FL. May 24, 2006 (Poster number C-244). We thank Edward O. Mason Jr. PhD and Avril Forsyth MD for reviewing the manuscript; Linda Lamberth, Mayra Quiñonez-Alvarado, Martha Carranza-Martinez and Maria Esther Carrillo-Macias for their technical support.

References

1. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. *Clin Infect Dis* 2002;35:547-555.
2. Di Fabio JL, Castaneda E, Agudelo CI, De La Hoz F, Hortal M, Camou T, et al. Evolution of *Streptococcus pneumoniae* serotypes and penicillin susceptibility in Latin America, Sireva-Vigia Group, 1993 to 1999. PAHO Sireva-Vigia Study Group. Pan American Health Organization. *Pediatr Infect Dis J* 2001;20:959-967.
3. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. *Pediatr Infect Dis J* 2000;19:187-195.
4. O'Brien KL, Shaw J, Weatherholtz R, Reid R, Watt J, Croll J, et al. Epidemiology of invasive *Streptococcus pneumoniae* among Navajo children in the era before use of conjugate pneumococcal vaccines, 1989-1996. *Am J Epidemiol* 2004;160:270-278.
5. Al Mazrou A, Twum-Danso K, Al Zamil F, Kambal A. *Streptococcus pneumoniae* serotypes/serogroups causing invasive disease in Riyadh, Saudi Arabia: extent of coverage by pneumococcal vaccines. *Ann Saudi Med* 2005;25:94-99.
6. Wasfy MO, Pimentel G, Abdel-Maksoud M, Russell KL, Barrozo CP, Klena JD, et al. Antimicrobial susceptibility and serotype distribution of *Streptococcus pneumoniae* causing meningitis in Egypt, 1998-2003. *J Antimicrob Chemother* 2005;55:958-964.
7. Hortal M, Ruvinsky R, Rossi A, Agudelo CI, Castaneda E, Brandileone C, et al. Impact of *Streptococcus pneumoniae* on pneumonia in Latin American children. Sireva-Vigia Group. *Rev Panam Salud Publica* 2000;8:185-195.
8. Dagan R, Kayhty H, Wuorimaa T, Yaich M, Bailleux F, Zamir O, et al. Tolerability and immunogenicity of an eleven valent mixed carrier *Streptococcus pneumoniae* capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. *Pediatr Infect Dis J* 2004;23:91-98.
9. Brown SD, Rybak MJ. Antimicrobial susceptibility of *Streptococcus pneumoniae*, *Streptococcus pyogenes* and *Haemophilus influenzae* collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. *J Antimicrob Chemother* 2004;54 Suppl 1:i7-15.
10. Clinical and Laboratory Standards Institute. Clinical and Laboratory Standards Institute/NCCLS. Performance Standards for antimicrobial susceptibility testing; Sixteenth Informational Supplement. CLSI/NCCLS document M100-S16. Ninth Edition. Wayne, PA: Clinical and Laboratory Standards Institute/NCCLS, 2006.
11. Lauderdale TL, Wagener MM, Lin HM, Huang IF, Lee WY, Hsieh KS, et al. Serotype and antimicrobial resistance patterns of *Streptococcus pneumoniae* isolated from Taiwanese children: comparison of nasopharyngeal and clinical isolates. *Diagn Microbiol Infect Dis* 2006;56:421-426.
12. Stratchounski LS, Kretchikova OI, Kozlov RS, Reshedko GK, Stetsiouk OU, Tarasova GD, et al. Antimicrobial resistance of *Streptococcus pneumoniae* isolated from healthy children in day-care centers: results of a multicenter study in Russia. *Pediatr Infect Dis J* 2000;19:196-200.
13. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. *JAMA* 2007;297:1784-1792.
14. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of *Streptococcus pneumoniae* in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. *Antimicrob Agents Chemother* 2001;45:1721-1729.